PTAB Upholds Sloan Kettering’s Cancer Immunotherapy Patent, PTAB Litigation Blog

Visit the PTAB Litigation Blog.

On December 16, 2016, the PTAB issued a final written decision in case IPR2015-01719, upholding all the claims of U.S. Patent 7,446,190, owned by Sloan Kettering Institute for Cancer Research (“Sloan”) and challenged by Kite Pharma Inc. ("Kite").  The Board determined that Kite did not prove that any of the claims were unpatentable as obvious and did not consider Sloan’s arguments regarding objective evidence of nonobviousness.

Read the full article at

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.